Are Series E, F and G a Stigma?
Rounds and Rounds They Go, And Where They Stop ...
By Catherine Hollingsworth
Monday, May 18, 2009
For cash-starved biotechs that have not yet found a parter or buyer, and are not in the running for any grant money or government contracts, there may be few options for survival in today's economy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.